Affymetrix Shares Decline on Downgrade from JP Morgan | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Shares of microarray firm Affymetrix tumbled about 7 percent after investment firm JP Morgan downgraded the company to "underweight" from "neutral."

In mid-afternoon trading, shares of the Santa Clara, Calif., firm's stock were down to $4.71 from $5.05 at the close of the market on Monday. More than 1.3 million shares had been traded, up from an average daily volume of less than 900,000 shares during the past three months.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.